Inflammatory Biomarkers in Sputum Predict COPD Exacerbations.
(2013) In Lung 191(4). p.413-416- Abstract
- INTRODUCTION: Exacerbations in chronic obstructive pulmonary disease (COPD) reduce quality of life and are associated with a more rapid deterioration of the disease. It is desirable to predict an oncoming exacerbation before it occurs. The aim of the present study was to identify biomarkers that may predict a forthcoming exacerbation. MATERIALS AND METHODS: Forty-three patients with COPD in their stable state were included and followed up monthly until exacerbation, or for a maximum of 6 months. The patients come for an extra visit (prior to a scheduled visit) when exacerbated. The patients completed the questionnaires CCQ and MRC. Exhaled breath condensate (EBC) was collected followed by spirometry, impulse oscillometry, and sputum... (More)
- INTRODUCTION: Exacerbations in chronic obstructive pulmonary disease (COPD) reduce quality of life and are associated with a more rapid deterioration of the disease. It is desirable to predict an oncoming exacerbation before it occurs. The aim of the present study was to identify biomarkers that may predict a forthcoming exacerbation. MATERIALS AND METHODS: Forty-three patients with COPD in their stable state were included and followed up monthly until exacerbation, or for a maximum of 6 months. The patients come for an extra visit (prior to a scheduled visit) when exacerbated. The patients completed the questionnaires CCQ and MRC. Exhaled breath condensate (EBC) was collected followed by spirometry, impulse oscillometry, and sputum induction. RESULTS: Twenty-five patients had an exacerbation within the 6-month period. Leukotriene B4 in sputum was the only biomarker that was increased at the visit prior to exacerbation compared to at the stable phase (p = 0.05). There also was a tendency for a similar but not significant increase in the sputum levels of 8-isoprostane, myeloperoxidase activity, and interleukin-8, as well as additional increases during exacerbation. Sputum purulence was not increased until exacerbation (p = 0.02). In contrast, none of the inflammatory biomarkers in EBC, the quality-of-life questionnaire score, CRP, spirometric parameters, or impulse oscillometry parameters were increased at the visit prior to exacerbation compared to the values at the stable phase. CONCLUSION: Sputum biomarkers, especially leukotriene B4, could be used as predictors of a forthcoming exacerbation and worsening of COPD. This would be of great value for the patient, who may be a subject for early treatment and thereby avoid a progression of the disease. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3804328
- author
- Tufvesson, Ellen LU ; Ekberg, Marie LU and Bjermer, Leif LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Lung
- volume
- 191
- issue
- 4
- pages
- 413 - 416
- publisher
- Springer
- external identifiers
-
- wos:000321916800014
- pmid:23689877
- scopus:84880795721
- pmid:23689877
- ISSN
- 1432-1750
- DOI
- 10.1007/s00408-013-9473-5
- language
- English
- LU publication?
- yes
- id
- b181dbe9-ea6c-4459-87c3-1f40860a46c0 (old id 3804328)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23689877?dopt=Abstract
- date added to LUP
- 2016-04-01 10:30:45
- date last changed
- 2022-01-25 23:54:22
@article{b181dbe9-ea6c-4459-87c3-1f40860a46c0, abstract = {{INTRODUCTION: Exacerbations in chronic obstructive pulmonary disease (COPD) reduce quality of life and are associated with a more rapid deterioration of the disease. It is desirable to predict an oncoming exacerbation before it occurs. The aim of the present study was to identify biomarkers that may predict a forthcoming exacerbation. MATERIALS AND METHODS: Forty-three patients with COPD in their stable state were included and followed up monthly until exacerbation, or for a maximum of 6 months. The patients come for an extra visit (prior to a scheduled visit) when exacerbated. The patients completed the questionnaires CCQ and MRC. Exhaled breath condensate (EBC) was collected followed by spirometry, impulse oscillometry, and sputum induction. RESULTS: Twenty-five patients had an exacerbation within the 6-month period. Leukotriene B4 in sputum was the only biomarker that was increased at the visit prior to exacerbation compared to at the stable phase (p = 0.05). There also was a tendency for a similar but not significant increase in the sputum levels of 8-isoprostane, myeloperoxidase activity, and interleukin-8, as well as additional increases during exacerbation. Sputum purulence was not increased until exacerbation (p = 0.02). In contrast, none of the inflammatory biomarkers in EBC, the quality-of-life questionnaire score, CRP, spirometric parameters, or impulse oscillometry parameters were increased at the visit prior to exacerbation compared to the values at the stable phase. CONCLUSION: Sputum biomarkers, especially leukotriene B4, could be used as predictors of a forthcoming exacerbation and worsening of COPD. This would be of great value for the patient, who may be a subject for early treatment and thereby avoid a progression of the disease.}}, author = {{Tufvesson, Ellen and Ekberg, Marie and Bjermer, Leif}}, issn = {{1432-1750}}, language = {{eng}}, number = {{4}}, pages = {{413--416}}, publisher = {{Springer}}, series = {{Lung}}, title = {{Inflammatory Biomarkers in Sputum Predict COPD Exacerbations.}}, url = {{http://dx.doi.org/10.1007/s00408-013-9473-5}}, doi = {{10.1007/s00408-013-9473-5}}, volume = {{191}}, year = {{2013}}, }